Diurnal Group Live Discussion

iwatchandlisten 25 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP Another 20000 added yesterday,moving nicely!

bernstein.babe 25 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP Rallyyyyyy continues and with a laughable valuation of 34 Million (41p) the upside is still massive

bernstein.babe 24 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP DNL is well financed after cap raising a few weeks ago and more cash will come through new Partnerships for the large markets like USA which expected anytime now . Upcoming Milestones Alkindi launch in additional EU States during 2H 2019 US-NDA submission for Alkindi in Q4 2019 EMA submission for Chronocort approval in Q4 2019 US-Partner Deal for Alkindi could happen anytime now US-Partner Deal for Chronocort could happen anytime now Partner Deal(s) for Alkindi and Chronocort for RoW could happen anytime now Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI.

bernstein.babe 24 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP step by step going higher and with big news like partnership ,which means upfront payments which could be higher than the entire DNL valuation of 32 Million , then this stock will be unstoppable .I think 100p+ before year end is likely .GLTA Diurnal also expects additional progress for Alkindi®, with further country launches scheduled during 2019 to accelerate growth of revenues,along with a planned NDA submission in the US during Q4 2019.Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI. The US remains an important market for Diurnal’s late-stage pipeline focused on cortisol deficiency, with a combined market size for the treatment of CAH and paediatric AI estimated at $132m, and a future expansion opportunity in adult AI, which represents a $0.9bn market opportunity in the US.”

bernstein.babe 23 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP any dip at this ridiculous low price is a great buying opportunity …

bernstein.babe 22 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP up 14.4% booooooooooom ,dont miss the next FUM guys another potential 700%++ upside gem here . " target="blank" rel="nofollow">[link]

bernstein.babe 22 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP Welcome on board this one is a monster opportunity after cap raising like FUM was at 7p in Q4 2018 (now trading at 46p) and DNL is even a much bigger opp than FUM . I wouldnt be surprised to see this one trading above 100p before year end .Market cap of 29 million is a pure gift . hardmanandco.com DNL-Interim-update-25-April-2019.pdf 911.61 KB Based on our clearly stated assumptions, the net present value of the cashflows that could be generated from DNL’s first two products alone equates to £248m. Riskadjustment to take account of their different stages of development in different territories reduces this to £139m, or 225p per share. “Diurnal also expects additional progress for Alkindi®, with further country launches scheduled during 2019 to accelerate growth of revenues,along with a planned NDA submission in the US during Q4 2019.Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI. The US remains an important market for Diurnal’s late-stage pipeline focused on cortisol deficiency, with a combined market size for the treatment of CAH and paediatric AI estimated at $132m, and a future expansion opportunity in adult AI, which represents a $0.9bn market opportunity in the US.”

iwatchandlisten 22 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP Thanks for the tip,I had a readup and thought this looks good so have had a little dabble with 20k and in profit ………owe you a drink!! Cheers!

bernstein.babe 22 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP up to 36p or 8.4%+ and valuation is still less than 30 million ,i think this undiscovered goldmine is definitely one of the most cheapest pharma gem you can get at this time .GL

bernstein.babe 19 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP Major breakout to 50p+ could happen anyime now .GL

bernstein.babe 19 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP Lots of Big News expected during second half which could this low float stock significantly higher .Potential US-Partnership for Chronocort and Alkindi could happen anytime now which means big upfront payments which alone could be as high or even more as the current entire valuation of only £27 million this shows how massive undervalued DNL is .GL On track to become a world-leading endocrinology specialty pharma company focused on ca. $10bn market opportunity •Initially targeting >$3bn market in cortisol deficiency •First product, Alkindi®, launched successfully in Germany and UK and generating revenues for the Company–Sales and marketing infrastructure in place for commercial launches across Europe •Second product, Chronocort®, completed European Phase III trial in Q3 2018 –European Medicines Agency positive opinion anticipated in 2020 •Seeking commercial partners in US and RoW to enter global markets •Commercial exclusivity until 2034 –orphan drug, regulatory and patents1 Diurnal also expects additional progress for Alkindi®, with further country launches scheduled during 2019 to accelerate growth of revenues,along with a planned NDA submission in the US during Q4 2019.Diurnal has received strong interest in Alkindi® and Chronocort® for the US and will continue to progress licensing discussions, including the potential for co-development of Chronocort® in the US, both in CAH and AI. The US remains an important market for Diurnal’s late-stage pipeline focused on cortisol deficiency, with a combined market size for the treatment of CAH and paediatric AI estimated at $132m, and a future expansion opportunity in adult AI, which represents a $0.9bn market opportunity in the US.

bernstein.babe 17 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP recommended Futura Medical (FUM) at 7p by end of 2018 now 8 months later the stock trading at 48p . DNL is another monster rebound play which has similar or even more upside potential than Futura , lots of big news expected during 2H 2019 like Partner Deals and submission of NDA and MAA for US and European approval . At £25 million valuation this undiscovered stock is even a great takeover candidate .STRONG BUY

bernstein.babe 17 Jul 2019

Diurnal (MC £25 M) 2 Big Drugs close to US & EU approval -Lifetime OPP Diurnal Group has a very low valuation of only £25 Million and attractive drugs in late stage development .This undiscovered stock has significant upside potential , the fair value is 100p+ right now and more on approval of Alkindi in USA and Chronocort in Europe both expected next year .Diurnal is definitely one if not the cheapest stock in the pharma sector .GL Alkindi for the treatment of paediatric adrenal insufficiency is approved in Europe (launched in UK & Germany other EU countries will follow shortly) , US-NDA submission expected in Q4 . Chronocort for the treament of congenital adrenal hyperplasia (CAH) MAA submission to EMA for European approval in Q4 and Start of US-Phase 3 also expected in 2H 2019 Management already in discussion to partner the Drugs in USA and RoW . Diurnal Group (DNL) Market Cap: £25 Million Cash: £11 Million Price: 28p Shares Out: 84.6 million Product Pipeline [link] Live Presentation July 2019 interim-results-presentation diurnal.co.uk interim-results-presentation-march-2019-pp.pdf 1710.33 KB [link] Filing a Market Authorisation Application (MAA) for Chronocort® in Europe by end 2019; Filing a New Drug Application (NDA) for Alkindi® in the US by end 2019; **Continuing the development of the European commercial organisation and roll-out of Alkindi® in Europe to maximise revenues; and ** Progressing licensing discussions for Alkindi® and Chronocort® in the US and the rest of the world hardmanandco.com DNL-Interim-update-25-April-2019.pdf 911.61 KB Clarity for Chronocort regulatory pathwayDiurnal (DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently unmet, with the aim of building a long-term ‘Adrenal Franchise’. The first product, Alkindi®, is being launched in key EU markets, and this was expected to be followed by the adult version, Chronocort®. After unexpected Phase III results, positive feedback from the EMA has cleared the path for regulatory submission of Chronocort for adult CAH in Europe before the end of 2019, and allowed DNL to revise the primary endpoint in theprotocol for the US Phase III trial. Largest Shareholder: IP Group Plc /Venture Capital/…34,410,147 Finance Wales Investments Ltd…11,534,888 Polar Capital LLP…6,622,631 Oceanwood Capital Management LLP…3,115,166 Richard Griffiths and controlled undertakings…4,999,615 Richard John Martin Ross, MD…1,554,925 Rowan Dartington & Co. Ltd. (Broker)…1,245,000 Rathbone Investment Management Ltd…354,000 Hargreaves Lansdown Stockbrokers Ltd…216,000 Octopus Investments Ltd…181,818

More4us 28 Oct 2018

Sell-off is chance to buy these #AIM stars on the cheap from interactive investor | 26th October 2018 15:16 #Diurnal #Group #PLC #DNL [link]

More4us 26 Oct 2018

@TopTradersADVFN #Diurnal #Group #PLC #DNL keep it 2 yourself as i want more m8